| Atherosclerosis risk factors related to hemodialysis duration and erythropoietin therapy. | |
| | |
MedLine Citation:
|
PMID: 11506457 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients undergoing hemodialysis are at risk for atherosclerosis and its complications. The aim of this study was to examine the effect of erythropoietin therapy and hemodialysis duration on some of the atherosclerotis risk factors. The patients were divided into four groups: I: patients undergoing hemodialysis for less than 10 years (n=22); II: patients undergoing hemodialysis for more than 10 years (n=17); III: patients on no erythropoietin (n=21); IV: patients on erythropoeitin therapy (n=18). A control group of 20 subjects was also examined. Triglycerides, total cholesterol, low-density lipoprotein and high-density lipoprotein, lipoprotein(a), apolipoprotein-A1, apolipoprotein-B and lipid peroxidation were examined. There was a significant increase in triglycerides, to 2.59+/-1.2 mmol/l (p<0.001) and in lipid peroxidation in hemodialysis patients, to 5.02+/-0.9 micromol/l vs. controls (p<0.001). Significantly elevated triglycerides and lipid peroxidation levels were found in the patients with longer hemodialysis duration. Triglycerides were elevated in group II vs. group I, to 2.90+/-1.0 mmol/l. (p<0.05). Lipid peroxidation in group II, 5.40+/-1.0 micromol/l, showed significant difference compared to group I (p<0.05). Erythropoietin treatment did not affect any of the examined parameters. These results indicate increased risk for atherosclerosis related to hemodialysis duration. Besides the renal disease itself, hemodialysis may also be one of the risk factors for atherosclerosis. |
| | |
Authors:
|
B Dejanova; V Filipce; P Dejanov; A Sikole; R Grozdanovski; V Maleska |
Related Documents
:
|
19363907 - Mid-dermal elastolysis in a patient undergoing chronic hemodialysis. 3079887 - Hypoxemia during hemodialysis in patients with impairment in pulmonary function. 2645537 - Specific imaging of dialysis-related amyloid deposits using 131i-beta-2-microglobulin. 9461047 - Outbreaks of gram-negative bacterial bloodstream infections traced to probable contamin... 16116107 - Silent ischemia in minor stroke and tia patients identified on mr imaging. 11438617 - Chromogranin a assay and (131)i-mibg scintigraphy for diagnosis and follow-up of pheoch... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical chemistry and laboratory medicine : CCLM / FESCC Volume: 39 ISSN: 1434-6621 ISO Abbreviation: Clin. Chem. Lab. Med. Publication Date: 2001 Jun |
Date Detail:
|
Created Date: 2001-08-16 Completed Date: 2002-02-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9806306 Medline TA: Clin Chem Lab Med Country: Germany |
Other Details:
|
Languages: eng Pagination: 484-6 Citation Subset: IM |
Affiliation:
|
Institute of Physiology, Medical Faculty, Skopje, Macedonia. betidej@soros.org.mk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Arteriosclerosis / etiology* Case-Control Studies Erythropoietin, Recombinant / adverse effects* Female Humans Lipid Peroxidation / drug effects Lipids / blood Male Middle Aged Renal Dialysis / adverse effects* Risk Factors Time Factors Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Erythropoietin, Recombinant; 0/Lipids; 0/Triglycerides |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stress tolerance test and SDS-PAGE for the analysis of urinary proteins in children and youths.
Next Document: Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.